KEY TAKEAWAYS
- The phase I trial aimed to evaluate the final efficacy and safety of first-in-class c-Met drug telisotuzumab vedotin combined with osimertinib in EGFR-mutated, c-Met-overexpressing NSCLC that progressed on prior osimertinib.
- The result demonstrated that the Teliso-V and osimertinib combo proved safe and effective in c-Met-overexpressing lung cancer after osimertinib failure, justifying further trials.
For a study, researchers aimed to evaluate the final efficacy and safety of first-in-class c-Met drug Telisotuzumab Vedotin(Teliso-V) combined with osimertinib in EGFR-mutated, c-Met-overexpressing non-small cell lung cancer(NSCLC) that progressed on prior osimertinib.
Patients (≥18 years) with advanced/metastatic NSCLC harboring EGFR mutations, c-Met overexpression (centrally assessed by IHC [Clinical Trial Assay]: 3+ in ≥25% tumor cells), and progression on osimertinib received T (intravenous every 2 weeks at 1.6 or 1.9 mg/kg) + O (oral 80 mg daily). Patients in the expansion phases had received up to two prior lines of therapy, including osimertinib.
Of 41 enrolled patients, data for 38 with adequate follow-up receiving T (1.6 mg/kg, n=20; 1.9 mg/kg, n=18) + O were analyzed. Median age was 60 years; 40/42/18% had received 1/2/>2 prior lines for metastatic NSCLC, including platinum-based therapy in 47%. Median number of T cycles (28 d/cycle) was 6 (range, 1–30). No dose-limiting toxicities (DLTs) were observed.
Treatment-related adverse events (TRAEs) occurred in 37 (97%; any grade [G]) patients; the most common (≥20%) were peripheral sensory neuropathy (50%), peripheral edema (21%), and nausea (21%). Grade ≥3 AEs were reported in 12 (32%) patients; the most common (≥5%) were anemia (11%) and peripheral motor and sensory neuropathy (5% each). AEs led to T discontinuation/interruption/reduction in 24/58/37% of patients. No deaths related to teliso or osimertinib were reported.
The result demonstrated that the telisotuzumab vedotin and osimertinib combo proved safe and effective in c-Met-overexpressing lung cancer after osimertinib failure, justifying further trials.
Source: https://cslide.ctimeetingtech.com/asia2023/attendee/confcal/show/session/45
Clinical Trial: https://clinicaltrials.gov/study/NCT02099058
Horinouchi I, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Blot V, Goldman JW. Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients with advanced EGFR-mutated, c-Met overexpressing non-small cell lung cancer: Final efficacy and safety updates. Presented at ESMO ASIA 2023; Presentation Number 515MO.
